On June 16, 2021 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") reported that it will host a virtual investor event on Wednesday, June 23, 2021, at 2 p.m. CEST / 8 a.m. EDT(Press release, Innate Pharma, JUN 16, 2021, View Source [SID1234584032]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature presentations and an interactive Q&A session from the Company’s executive leadership team as well as Martine Bagot, M.D., Ph.D., Professor and Head of the Dermatology Department at the Saint-Louis Hospital, University of Paris, France.

Pr. Bagot will present preliminary mycosis fungoides data from the Company’s Phase 2 TELLOMAK trial evaluating its lead product, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. This preliminary data will be presented as an oral presentation at the 16th International Conference on Malignant Lymphoma (16-ICML) on June 22.

Additionally, the Company’s Chief Scientific Officer, Pr. Eric Vivier, DVM, Ph.D., will present preclinical data from ANKETTM (Antibody-based NK cell Engager Therapeutics), Innate’s proprietary platform for developing next-generation, multi-functional NK cell engagers. These new data were presented at the Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting on June 10.